# Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease

> **NCT00909545** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 99 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Isradipine CR 5mg
- **DRUG:** Isradipine CR 10mg
- **DRUG:** Isradipine CR 20mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00909545
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-12
- **Final completion:** 2012-02
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2013-04-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00909545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00909545, "Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00909545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*